2018 Annual Meeting | C93 - Advances in Neurogenetics

Date Monday 04/23/18

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Matthew Harms, MD

Topic(s)

Learning Objectives Participants should obtain a broad overview of neurogenetic advances, familiarity with available tools in diagnostics, current understanding of disease mechanisms underlying hereditary developmental and degenerative neurologic disorders, treatment strategies, and expert opinions on practical and still-evolving approaches to neurogenetic disorders.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Interactive

Event Timeline
03:30 PM - 03:50 PM	Speaker	Overview 2018: Genetic Discoveries and Technological Advances Across Neurology Matthew Harms, MD
03:50 PM - 04:35 PM	Speaker	Focus Topic I: Genetic Advances in Hereditary Spastic Paraplegia Rebecca E. Schuele, MD
04:35 PM - 05:20 PM	Speaker	Focus Topic II: Genetic Advances in Epilepsy Tristan T. Sands, MD, PhD
05:20 PM - 05:30 PM	Q&A	Questions and Answers

Faculty Disclosures
Matthew Harms, MD	Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Harms has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Muscular Dystrophy Association. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Invitae. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Variant Bio. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for uniQure. Dr. Harms has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Littlepage Booth. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for O'Connor First. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Searcy Denney. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Ford, Parshall & Baker LLC . The institution of Dr. Harms has received research support from ALS Association. The institution of Dr. Harms has received research support from Ionis. The institution of Dr. Harms has received research support from ALS Finding a Cure. The institution of Dr. Harms has received research support from Target ALS.
Tristan T. Sands, MD, PhD	No disclosure on file
Rebecca E. Schuele, MD	No disclosure on file

��ɫ��

��ɫ��